ResMed Q4 revenue rises 9% to record $1.5 billion; quarterly dividend raised 10% to $0.66
ResMed reported fiscal fourth-quarter 2026 revenue of $1.46 billion, up 9% from a year earlier, and GAAP diluted earnings per share of $2.64, up 2%. Its board also declared a 10% dividend increase to $0.66 per share, with an ex-dividend date of August 19, 2026, which matters to shareholders receiving the payout.
Key points
- Q4 revenue $1.46 billion, up 9% (8% in constant currency); GAAP diluted EPS $2.64, up 2%
- Non-GAAP diluted EPS $2.95, up 16%; GAAP results include $42 million in Astral field safety notification expenses
- Quarterly dividend of $0.66 per share, record date August 20, 2026, payable September 24, 2026
- Company guides to more than $1.85 billion returned to shareholders through buybacks and dividends in fiscal 2027
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:30 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.